Ruijin Hospital — Shanghai
China's leading centre for haematology, endocrinology, and CAR-T therapy
Founded
1907
Beds
2,742
Location
Shanghai
About Ruijin
Ruijin Hospital, founded in 1907 as Guangci Hospital and now affiliated with Shanghai Jiao Tong University School of Medicine, is China's preeminent institution for haematology, endocrinology, and metabolic disease. Its CAR-T cell therapy programme — one of the most advanced in Asia — treats blood cancers that have relapsed after standard chemotherapy. In 2025, Ruijin became the first Chinese hospital to receive DNV DIAS international accreditation alongside its existing JCI certification.
Why International Patients Choose Ruijin
- ✓China's leading haematology centre — among the world's most experienced in CAR-T cell therapy for relapsed blood cancers
- ✓Triple accredited: Grade 3A, JCI, and DNV DIAS (2025) — the most internationally validated hospital in mainland China
- ✓International Medical Centre with direct billing for 20+ domestic and international insurance providers
- ✓Active clinical trials in CAR-T and next-generation immunotherapy — eligible patients may access cutting-edge treatments
- ✓Endocrinology and metabolic disease programme for complex diabetes, thyroid, and adrenal conditions
Specialties
Explore related treatment guides:
Accreditations & Standards
Grade 3A is China's highest hospital classification, awarded to institutions meeting the most rigorous standards in clinical quality, staffing, infrastructure, and patient safety. JCI accreditation adds an internationally recognised layer of certification accepted by most European insurers.
Getting There
Frequently Asked Questions
What blood cancers does Ruijin Hospital treat with CAR-T therapy?
Ruijin's haematology department offers CAR-T cell therapy primarily for relapsed or refractory B-cell lymphoma, multiple myeloma, and acute lymphoblastic leukaemia (ALL). Eligibility is assessed case-by-case based on prior treatment history, performance status, and disease characteristics.
How does CAR-T therapy at Ruijin compare in cost to Europe or the USA?
CAR-T therapy in Europe or the USA typically costs €300,000–€500,000 per treatment cycle. At Ruijin, comparable treatments cost significantly less — often 60–80% lower — partly because several CAR-T constructs approved in China were developed domestically and are not licensed products of Western pharmaceutical companies.
Does Ruijin Hospital accept patients who have already received chemotherapy abroad?
Yes. Ruijin regularly accepts referrals from patients who have completed initial chemotherapy or stem cell transplantation in their home country and are now seeking salvage therapy. Full medical records, treatment summaries, and pathology reports should be sent in advance for pre-assessment.
What insurance does Ruijin's International Medical Centre accept?
Ruijin's IMC has direct billing arrangements with over 20 domestic and international insurers. Patients with international health insurance should confirm overseas oncology coverage with their provider before travelling. Our coordinators can assist with pre-authorisation documentation.
Get a Free Treatment Assessment
Submit your case details and receive a personalised plan within 24 hours — including hospital recommendation, cost estimate, and next steps.